Judge lets challenge to FDA tobacco panel proceed

August 1, 2012 by MICHAEL FELBERBAUM

(AP) — A challenge by two of the largest U.S. cigarette makers alleging conflicts of interest in the Food and Drug Administration advisory panel's review of tobacco products can move forward, a federal judge has ruled.

In an order posted Wednesday, U.S. District Court Judge Richard Leon in Washington denied the FDA's motion to dismiss the suit filed by Lorillard Inc. and R.J. Reynolds Co. The suit filed last year alleges financial conflict of interest and bias by several members of the Tobacco Products Scientific Advisory Committee and asks the court to stop the federal agency from relying on the panel's recommendations.

The panel is tasked with advising the FDA on tobacco-related issues, including the public health impact of menthol cigarettes and dissolvable tobacco, two industry growth areas.

"Because of the limited number of viewpoints on these issues, the scientific — as opposed to political — nature of those viewpoints, and the distinct responsibilities of the committee, I believe I have sufficient standards which I can evaluate the agency's discretion," Leon wrote in his order.

Representatives for the FDA and R.J. Reynolds would not comment on pending litigation.

In a statement, Lorillard said: "The practice of appointing members to a government scientific advisory committee who have financial interests that violate conflict-of-interest laws and regulations should be subject to judicial review, as the court has now recognized."

The FDA won the authority to regulate tobacco in 2009. The law doesn't let the FDA ban nicotine or tobacco, just regulate what goes into tobacco products, require the ingredients be publicized and limit how tobacco is marketed, especially to young people. The agency's panels advise it on scientific issues. It doesn't have to follow their recommendations, but usually does.

In the suit, the tobacco companies allege that the panel fails to meet the federal requirements that committee members should be fairly balanced and not inappropriately influenced by any special interest. The suit specifically alleges that some committee members have conflicts of interest because they were paid expert witnesses in anti-tobacco lawsuits and have financial ties to pharmaceutical companies that make smoking-cessation products.

The agency, however, argued that the panel meets federal standards and that the cigarette makers' "alleged injuries are entirely speculative," and "not fairly traceable." The FDA also argued that the court lacks jurisdiction to review the conflict of interest challenged raised by the companies.

Several cigarette makers, including Altria Group Inc., parent company of Philip Morris USA, had previously asked the federal agency to remove members of the panel for conflicts of interest. Altria is not part of the suit.

Lorillard, based in Greensboro, North Carolina, holds about 35 percent of the U.S menthol market with its top-selling Newport brand. R.J. Reynolds and its parent company, Reynolds American Inc., based in Winston-Salem, North Carolina, sell brands like Camel and Pall Mall, as well as several dissolvable tobacco products — is finely milled tobacco pressed into shapes like tablets that slowly dissolve in a user's mouth.

Vince Willmore, a spokesman for the Campaign for Tobacco-Free Kids, said the suit is an effort by the tobacco companies to "obstruct effective policies to reduce tobacco use and to discredit anyone who advocates such policies."

The suit comes amid two advisory panel reports mandated by the law that gave the FDA authority to regulate the tobacco industry.

A panel report issued last March said removing menthol cigarettes from the market would benefit public health because the flavoring has led to an increase in smokers__ particularly among teens, African Americans, and those with low incomes. It also said that they make it harder for them to quit. The report, however, said menthol smokers are not likely to be at a higher risk of disease or exposed to a greater number of toxins. The FDA is conducting an independent review on the issue.

In a report earlier this year, the panel said that dissolvable tobacco products could reduce health risks compared with smoking cigarettes but also have the potential to increase the overall number of tobacco users. Dissolvable are gaining the attention of tobacco companies looking to make up for a decline in cigarette use as smokers face tax hikes, growing health concerns, smoking bans and social stigma

Explore further: FDA: tobacco companies must report chemicals


Related Stories

FDA: tobacco companies must report chemicals

March 30, 2012
(AP) -- Tobacco companies will be required to report the levels of dangerous chemicals found in cigarettes, chew and other products under the latest rules designed to tighten regulation of the tobacco industry.

Tobacco firms sue US over graphic cigarette labels

August 17, 2011
Four tobacco companies filed a lawsuit against the US Food and Drug Administration (FDA) on Tuesday over what they say are unconstitutional requirements for warning labels on US cigarette packaging.

Recommended for you

Concern with potential rise in super-potent cannabis concentrates

July 21, 2017
University of Queensland researchers are concerned the recent legalisation of medicinal cannabis in Australia may give rise to super-potent cannabis concentrates with associated harmful effects.

Findings link aldosterone with alcohol use disorder

July 18, 2017
A new study led by scientists at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, demonstrates that aldosterone, a hormone produced in the adrenal glands, may contribute ...

Depression among young teens linked to cannabis use at 18

July 17, 2017
A study looking at the cumulative effects of depression in youth, found that young people with chronic or severe forms of depression were at elevated risk for developing a problem with cannabis in later adolescence.

Why does prenatal alcohol exposure increase the likelihood of addiction?

July 7, 2017
One of the many negative consequences when fetuses are exposed to alcohol in the womb is an increased risk for drug addiction later in life. Neuroscientists in the University at Buffalo Research Institute on Addictions are ...

Researchers say U.S. policies on drugs and addiction could use a dose of neuroscience

June 23, 2017
Tens of thousands of Americans die from drug overdoses every year – around 50,000 in 2015 – and the number has been steadily climbing for at least the last decade and a half, according to the National Institute on Drug ...

Study provides further support for genetic factors underlying addictions

June 13, 2017
Impairment of a particular gene raises increases susceptibility to opioid addiction liability as well as vulnerability to binge eating according to a new study.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.